2025
A Perspective on the MARS2 Trial
Lim E, Opitz I, Woodard G, Bueno R, de Perrot M, Flores R, Gill R, Jablons D, Pass H. A Perspective on the MARS2 Trial. Journal Of Thoracic Oncology 2025, 20: 262-272. PMID: 39772349, DOI: 10.1016/j.jtho.2024.12.014.Peer-Reviewed Original ResearchConceptsPleural mesotheliomaPleurectomy decorticationTrial interpretationAssemble individualsAssociated with worse survivalPhase 3 randomized controlled trialsTime of randomizationTeam leadersResectable PMHistological subtypesPreoperative stagingWorse survivalSurgical mortalityConsensus guidelinesTeamAdverse eventsFacilitationChemotherapyPayer's willingnessSurgical communityTrialsSurgeryMesotheliomaQuality assuranceDecortication
2021
MO01.13 Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit from Adjuvant Chemotherapy
Woodard G, Kratz J, Haro G, Gubens M, Blakely C, Jones K, Mann M, Jablons D. MO01.13 Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit from Adjuvant Chemotherapy. Journal Of Thoracic Oncology 2021, 16: s21. DOI: 10.1016/j.jtho.2020.10.061.Peer-Reviewed Original Research
2018
P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy
Woodard G, Wang S, Kratz J, Haro G, Gubens M, Blakely C, Jahan T, Jones K, Mann M, Jablons D. P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy. Journal Of Thoracic Oncology 2018, 13: s835. DOI: 10.1016/j.jtho.2018.08.1487.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply